Perrigo Company plc

PRGO ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $74.5M $-398.6M $-1.42B $7.5M $-8.4M $-6.4M $-44.4M $-21.0M
Depreciation & Amortization $95.8M $83.3M $85.9M $85.4M $86.3M $79.9M $80.3M $82.3M
Depreciation $41.4M $28.9M — — $29.3M $24.9M — —
Amortization $54.5M $54.5M $55.5M $55.8M $56.6M $54.8M $55.1M $57.5M
Stock-Based Compensation $6.8M $14.4M $13.0M $13.2M $16.8M $11.6M $19.9M $5.9M
Net Cash from Operating Activities $82.6M $-113.6M $175.4M $51.7M $75.9M $-64.5M $312.6M $42.2M
Investing Activities
Capital Expenditures $14.3M $13.8M $26.8M $21.9M $19.2M $25.5M $37.7M $27.1M
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $349.4M $-12.4M $-24.5M $-21.4M $-3.8M $-25.7M $-37.1M $212.7M
Financing Activities
Dividends Paid $40.2M $39.9M $39.9M $39.9M $38.9M $40.6M $39.6M $37.6M
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-388.9M $-45.3M $-54.4M $-50.3M $-54.0M $-61.8M $-1.15B $653.3M
Net Change in Cash $40.2M $-174.4M $99.5M $-19.8M $37.1M $-141.7M $-904.7M $920.7M
Free Cash Flow $68.3M $-127.4M $148.6M $29.8M $56.7M $-90.0M $274.9M $15.1M
← Newer Page 1 of 7 Older →